Galapagos Enters Strategic Collaboration Agreement With Thermo Fisher Scientific To Further Expand Decentralized CAR-T Manufacturing Network In The US

• Thermo Fisher Scientific to Provide CAR-T Manufacturing and Kitting Services for Galapagos ' Point-of-Care CAR-T Product Candidate in the San Francisco Region
• Agreement follows previously announced collaboration with Landmark Bio for decentralized CAR-T production in the Boston region

Mechelen (GLOBE NEWSWIRE) - Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (NYSE: TMO) (“Thermo Fisher ” ) for the decentralized manufacturing of Galapagos' point-of-care CAR-T product candidate in the San Francisco region.

Under the terms of the agreement, Thermo Fisher will provide GMP manufacturing, as well as BioServices and Specialty Logistics for Galapagos' CAR-T hemato-oncology clinical program in the San Francisco region, effective January 2024. Galapagos will initiate the technology transfer to expand the manufacturing operations of Thermo Fisher possible. This collaboration follows Galapagos' agreement with Landmark Bio for decentralized CAR-T manufacturing in the Boston region, announced in November 2023.

“As we continue to execute on our global CAR-T expansion strategy, we are thrilled to partner with Thermo Fisher, a leader in accelerating life sciences research and the development of life-changing therapies,” said Dr. Paul Stoffels ¹ , CEO and Chairman of Galapagos. “Together, we will establish a decentralized CAR-T manufacturing network in the San Francisco area to support the rollout of our pivotal clinical trials and increase our market readiness. This collaboration furthers Galapagos' commitment to better meet patient needs and make CAR-T therapies available to more patients through rapid delivery of suitable CAR-T cells.”

“This collaboration marks the beginning of an exciting journey to support Galapagos with their decentralized manufacturing strategy,” said Jennifer Cannon, president of Commercial Operations of Thermo Scientific's Pharma Services organization. “Through continued investment in our broad range of cell and gene therapy capabilities, our recently opened San Francisco facility provides expertise and flexibility in manufacturing, as well as BioServices & Specialty Logistics, to support customers like Galapagos from early development work through commercialization. ”

The financial terms of the agreement were not disclosed.

About Galapagos' Decentralized CAR-T Manufacturing Platform
Galapagos' decentralized, innovative point-of-care CAR-T manufacturing platform offers the potential for delivery of appropriate cells within a median vein-to-infusion time of 7 days, providing greater control through the doctor and an exceptional patient experience. The platform consists of an end-to-end xCellit™ workflow management and monitoring software system, a decentralized, functionally closed, automated production platform for cell therapies (using Lonza's Cocoon®) and a proprietary quality control, testing and release strategy.

About Galapagos
We are a global biotechnology company with operations in Europe and the US committed to developing breakthrough medicines that extend life and quality of life. We focus on high unmet medical needs and combine the most compelling science, technology and collaborative approaches to create a deep pipeline of the best small molecules, CAR-T therapies and biologics in oncology and immunology. With capabilities from lab to patient, including a decentralized point-of-care CAR-T manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders. For more information, visit www.glpg.com or follow us on LinkedIn or X (formerly Twitter).

Forward-looking statements
This press release contains forward-looking statements within the meaning of the amended Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made by the use of words or phrases such as "will," "target" and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding the collaboration between Galapagos and Thermo Fisher. Forward-looking statements may involve unknown and known risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. These risks, uncertainties and other factors include, without limitation, the risk that Galapagos' expectations regarding the collaboration with Thermo Fisher, including the potential benefits of such [collaboration], may be incorrect, the inherent uncertainties associated related to competitive developments and regulatory approval requirements, risks associated with Galapagos' dependence on collaborations with third parties (including its collaboration partner Lonza), as well as the risks and uncertainties mentioned in the annual report on Form 20-F of Galapagos for the year ended December 31, 2022 and subsequent filings with the Securities and Exchange Commission. All statements other than statements of historical fact are statements that may be deemed forward-looking statements. The forward-looking statements contained herein are based on the current expectations and beliefs of Galapagos' management and speak only as of the date hereof, and Galapagos undertakes no obligation to update or publicly release any forward-looking statements to reflect new information or subsequent events. , circumstances or changes in expectations, unless required to do so by law or regulation.

¹ In this press release 'Dr. Paul Stoffels' are read as 'Dr. Paul Stoffels, acting through Stoffels IMC BV'.